Type 1 diabetes mellitus (T1DM) can cause several complications, among them myopathy, which can appear even in adolescents. This is of importance, since skeletal muscle is the largest of the insulin-sensitive tissues and thus plays a significant role in glucose homeostasis. A prime regulator of skeletal muscle mass is myostatin, a protein which has a negative role in skeletal muscle development but also in glucose homeostasis, causing insulin resistance. Since myopathy is a complication of T1DM and myostatin is a fundamental regulator of skeletal muscle and is also involved in glucose homeostasis, we investigated the serum levels of myostatin in children with T1DM.
We determined myostatin serum levels using ELISA in 87 children with T1DM aged 10.62 ± 3.94 years, and in 75 healthy children aged 10.46 ± 3.32 years old.
Myοstatin was significantly elevated in T1DM compared to the healthy control children (23.60 ± 7.70 vs 16.74 ± 6.95 ng/ml, p < 0.0001). Myostatin was not correlated with body mass index (BMI) SD or hemoglobin A1c (HbA1c).
Children with T1DM have significantly higher serum levels of myostatin compared to healthy children of the same age and BMI SD. The elevated myostatin in T1DM could reflect impaired muscle function and/or glucose metabolism, or could represent a homeostatic mechanism.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Availability of data and material
All authors confirm that all data and materials as well as software application support their published claims and comply with field standards.
SPSS version 25 license from the University of Patras, Greece. WHO AnthroPlus is available free from the WHO internet page.
Katz LD, Glickman MG, Rapoport S, Ferrannini E, DeFronzo RA (1983) Splanchnic and peripheral disposal of oral glucose in man. Diabetes 32:675–679. https://doi.org/10.2337/diab.32.7.675
Baron AD, Brechtel G, Wallace P, Edelman SV (1988) Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255:E769–E774. https://doi.org/10.1152/ajpendo.1988.255.6.E769
Krause MP, Riddell MC, Hawke TJ (2011) Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes 12:345–364. https://doi.org/10.1111/j.1399-5448.2010.00699.x
Andersen H, Gadeberg PC, Brock B, Jakobsen J (1997) Muscular atrophy in diabetic neuropathy: a stereological magnetic resonance imaging study. Diabetologia 40:1062–1069. https://doi.org/10.1007/s001250050788
Andersen H, Schmitz O, Nielsen S (2005) Decreased isometric muscle strength after acute hyperglycaemia in Type 1 diabetic patients. Diabet Med 22:1401–1407. https://doi.org/10.1111/j.1464-5491.2005.01649.x
Maratova K, Soucek O, Matyskova J et al (2018) Muscle functions and bone strength are impaired in adolescents with type 1 diabetes. Bone 106:22–27. https://doi.org/10.1016/j.bone.2017.10.005
McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83–90. https://doi.org/10.1038/387083a0
Grobet L, Pirottin D, Farnir F et al (2003) Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 35:227–238. https://doi.org/10.1002/gene.10188
Reisz-Porszasz S, Bhasin S, Artaza JN et al (2003) Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 285:E876–E888. https://doi.org/10.1152/ajpendo.00107.2003
Guo T, Bond ND, Jou W, Gavrilova O, Portas J, McPherron AC (2012) Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 61:2414–2423. https://doi.org/10.2337/db11-0915
Wilkes JJ, Lloyd DJ, Gekakis N (2009) Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 58:1133–1143. https://doi.org/10.2337/db08-0245
Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC (2009) Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 4:e4937. https://doi.org/10.1371/journal.pone.0004937
Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA (2009) Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 58:30–38. https://doi.org/10.2337/db08-0943
Garikipati DK, Rodgers BD (2012) Myostatin inhibits myosatellite cell proliferation and consequently activates differentiation: evidence for endocrine-regulated transcript processing. J Endocrinol 215:177–187. https://doi.org/10.1530/JOE-12-0260
Wang F, Liao Y, Li X, Ren C, Cheng C, Ren Y (2012) Increased circulating myostatin in patients with type 2 diabetes mellitus. J Huazhong Univ Sci Technolog Med Sci 32:534–539. https://doi.org/10.1007/s11596-012-0092-9
Amor M, Itariu BK, Moreno-Viedma V et al (2018) Serum myostatin is upregulated in obesity and correlates with insulin resistance in humans. Exp Clin Endocrinol Diabetes
Tanaka M, Masuda S, Yamakage H et al (2018) Role of serum myostatin in the association between hyperinsulinemia and muscle atrophy in Japanese obese patients. Diabetes Res Clin Pract 142:195–202. https://doi.org/10.1016/j.diabres.2018.05.041
Ehehalt S, Schweizer R, Blumenstock G et al (2011) Investigation of myostatin serum levels before and after a 6-month lifestyle intervention program in obese children. Exp Clin Endocrinol Diabetes 119:238–242
Dial AG, Monaco CMF, Grafham GK et al (2020) Muscle and serum myostatin expression in type 1 diabetes. Physiol Rep 8:e14500. https://doi.org/10.14814/phy2.14500
Yki-Jarvinen H, Koivisto VA (1986) Natural course of insulin resistance in type I diabetes. N Engl J Med 315:224–230. https://doi.org/10.1056/NEJM198607243150404
Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV (1986) Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315:215–219. https://doi.org/10.1056/NEJM198607243150402
Donga E, Dekkers OM, Corssmit EP, Romijn JA (2015) Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 173:101–109. https://doi.org/10.1530/EJE-14-0911
Peltoniemi P, Yki-Jarvinen H, Oikonen V et al (2001) Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. Diabetes 50:1371–1377. https://doi.org/10.2337/diabetes.50.6.1371
Nadeau KJ, Regensteiner JG, Bauer TA et al (2010) Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 95:513–521. https://doi.org/10.1210/jc.2009-1756
Schauer IE, Snell-Bergeon JK, Bergman BC et al (2011) Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60:306–314. https://doi.org/10.2337/db10-0328
Cree-Green M, Stuppy JJ, Thurston J et al (2018) Youth with type 1 diabetes have adipose, hepatic, and peripheral insulin resistance. J Clin Endocrinol Metab 103:3647–3657. https://doi.org/10.1210/jc.2018-00433
Bjornstad P, Schäfer M, Truong U et al (2018) Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 138:2895–2907. https://doi.org/10.1161/CIRCULATIONAHA.118.035525
Monaco CMF, Hughes MC, Ramos SV et al (2018) Altered mitochondrial bioenergetics and ultrastructure in the skeletal muscle of young adults with type 1 diabetes. Diabetologia 61:1411–1423. https://doi.org/10.1007/s00125-018-4602-6
Monaco CMF, Bellissimo CA, Hughes MC et al (2020) Sexual dimorphism in human skeletal muscle mitochondrial bioenergetics in response to type 1 diabetes. Am J Physiol Endocrinol Metab 318:E44–E51. https://doi.org/10.1152/ajpendo.00411.2019
Heyman E, Daussin F, Wieczorek V et al (2020) Muscle oxygen supply and use in type 1 diabetes, from ambient air to the mitochondrial respiratory chain: is there a limiting step? Diabetes Care 43:209–218. https://doi.org/10.2337/dc19-1125
Cree-Green M, Newcomer BR, Brown MS et al (2015) Delayed skeletal muscle mitochondrial ADP recovery in youth with type 1 diabetes relates to muscle insulin resistance. Diabetes 64:383–392. https://doi.org/10.2337/db14-0765
Assyov YS, Velikova TV, Kamenov ZA (2017) Myostatin and carbohydrate disturbances. Endocr Res 42:102–109. https://doi.org/10.1080/07435800.2016.1198802
Brandt C, Nielsen AR, Fischer CP, Hansen J, Pedersen BK, Plomgaard P (2012) Plasma and muscle myostatin in relation to type 2 diabetes. PLoS ONE 7:e37236. https://doi.org/10.1371/journal.pone.0037236
Garcia-Fontana B, Reyes-Garcia R, Morales-Santana S et al (2016) Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine 52:54–62. https://doi.org/10.1007/s12020-015-0758-8
Coleman SK, Rebalka IA, D’Souza DM, Deodhare N, Desjardins EM, Hawke TJ (2016) Myostatin inhibition therapy for insulin-deficient type 1 diabetes. Sci Rep 6:32495. https://doi.org/10.1038/srep32495
Jeong J, Conboy MJ, Conboy IM (2013) Pharmacological inhibition of myostatin/TGF-β receptor/pSmad3 signaling rescues muscle regenerative responses in mouse model of type 1 diabetes. Acta Pharmacol Sin 34:1052–1060. https://doi.org/10.1038/aps.2013.67
Nuutila P, Knuuti J, Ruotsalainen U et al (1993) Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetes. Am J Physiol 264:E756–E762. https://doi.org/10.1152/ajpendo.1993.264.5.E756
Kelley DE, Goodpaster B, Wing RR, Simoneau JA (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130–E1141. https://doi.org/10.1152/ajpendo.1999.277.6.E1130
Zhang C, McFarlane C, Lokireddy S et al (2012) Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 55:183–193. https://doi.org/10.1007/s00125-011-2304-4
Bonala S, Lokireddy S, McFarlane C, Patnam S, Sharma M, Kambadur R (2014) Myostatin induces insulin resistance via Casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake. J Biol Chem 289:7654–7670. https://doi.org/10.1074/jbc.M113.529925
Cleasby ME, Jarmin S, Eilers W et al (2014) Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am J Physiol Endocrinol Metab 306:E814–E823. https://doi.org/10.1152/ajpendo.00586.2013
We thank Dimitra Kritikou for her excellent technical assistance.
Ethics approval and consent to participate
The procedures used in this study were in line with principles of the Declaration of Helsinki. The study protocol was approved by the Ethical committee of the University Hospital of Patras, Greece. All children and their parents were informed, and written consent was obtained before participation in the study.
Consent for publication
Not applicable since participated subjects cannot be identified.
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Efthymiadou, A., Vasilakis, IA., Giannakopoulos, A. et al. Myostatin serum levels in children with type 1 diabetes mellitus. Hormones (2021). https://doi.org/10.1007/s42000-021-00317-y